Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tcm.2020.12.004 http://scihub22266oqcxt.onion/10.1016/j.tcm.2020.12.004 33338635!7836332!33338635     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33338635&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Trends+Cardiovasc+Med 2021 ; 31 (3): 143-160 Nephropedia Template TP {{tp|p=33338635|t=2021. COVID-19 and thrombosis: From bench to bedside |pdf=|usr=}}{{33338635}} gab.com Text COVID-19 and thrombosis: From bench to bedside JO: Trends Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=33338635 #FOAvip Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link between COVID-19 and thrombosis is attracting attention from the broad scientific community. In this review we will analyze the current available knowledge of the association between COVID-19 and thrombosis. We will highlight mechanisms at both molecular and cellular levels that may explain this association. In addition, the article will review the antithrombotic properties of agents currently utilized or being studied in COVID-19 management. Finally, we will discuss current professional association guidance on prevention and treatment of thromboembolism associated with COVID-19. Twit Text FOAVip COVID-19 and thrombosis: From bench to bedside ????Trends Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=33338635 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33338635 #FOAvip English Wikipedia <ref>{{Cite pmid|33338635}}</ref> COVID-19 and thrombosis: From bench to bedside #MMPMID33338635 Ali MAM; Spinler SA Trends Cardiovasc Med 2021[Apr]; 31 (3): 143-160 PMID33338635show ga Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link between COVID-19 and thrombosis is attracting attention from the broad scientific community. In this review we will analyze the current available knowledge of the association between COVID-19 and thrombosis. We will highlight mechanisms at both molecular and cellular levels that may explain this association. In addition, the article will review the antithrombotic properties of agents currently utilized or being studied in COVID-19 management. Finally, we will discuss current professional association guidance on prevention and treatment of thromboembolism associated with COVID-19. |Anticoagulants/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*complications/diagnosis[MESH] |Fibrinolytic Agents/*therapeutic use[MESH] |Humans[MESH] |SARS-CoV-2/*pathogenicity[MESH] |Thromboembolism/drug therapy/virology[MESH]COVID-19 and thrombosis: From bench to bedside (epmc).pdf DeepDyve Pubget Overpricing